{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:31:22Z","timestamp":1771511482744,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Pioneer AND leading goose R&D Program of Zhejiang","award":["2025C02137"],"award-info":[{"award-number":["2025C02137"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10067-025-07581-y","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T07:38:15Z","timestamp":1752651495000},"page":"3655-3665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of anti-TNF treatment failure in intestinal Beh\u00e7et's disease: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Wenyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiudi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinli","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huogen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-4001","authenticated-orcid":false,"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"7581_CR1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi G, Bettiol A, Hatemi G, Prisco D (2024) Beh\u00e7et\u2019s syndrome. Lancet 403:1093\u20131108. https:\/\/doi.org\/10.1016\/s0140-6736(23)02629-6","journal-title":"Lancet"},{"key":"7581_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/14397595.2015.1056956","volume":"26","author":"Y Kimura","year":"2016","unstructured":"Kimura Y, Asako K, Kikuchi H, Kono H (2016) Characteristics of patients with intestinal Beh\u00e7et\u2019s disease requiring treatment with immunosuppressants or anti-TNF\u03b1 antibody. Mod Rheumatol 26:132\u2013137. https:\/\/doi.org\/10.3109\/14397595.2015.1056956","journal-title":"Mod Rheumatol"},{"key":"7581_CR3","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3748\/wjg.v21.i13.3801","volume":"21","author":"W Skef","year":"2015","unstructured":"Skef W, Hamilton MJ, Arayssi T (2015) Gastrointestinal Beh\u00e7et\u2019s disease: a review. World J Gastroenterol 21:3801\u20133812. https:\/\/doi.org\/10.3748\/wjg.v21.i13.3801","journal-title":"World J Gastroenterol"},{"key":"7581_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M et al (2020) Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol 55:679\u2013700. https:\/\/doi.org\/10.1007\/s00535-020-01690-y","journal-title":"J Gastroenterol"},{"key":"7581_CR5","doi-asserted-by":"publisher","first-page":"S698","DOI":"10.1016\/S0016-5085(10)63212-X","volume":"138","author":"JJ Park","year":"2010","unstructured":"Park JJ, Cheon JH, Moon CM, Lee JH, Jeon SM, Bok HJ et al (2010) W1321 Long-Term Clinical Outcomes After the First Course of Corticosteroid Therapy in Patients With Moderate to Severe Intestinal Behget\u2019s Disease. Gastroenterology 138:S698\u2013S699","journal-title":"Gastroenterology"},{"key":"7581_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","volume":"186","author":"N Gholijani","year":"2017","unstructured":"Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E (2017) An elevated pro-inflammatory cytokines profile in Behcet\u2019s disease: A multiplex analysis. Immunol Lett 186:46\u201351. https:\/\/doi.org\/10.1016\/j.imlet.2016.12.001","journal-title":"Immunol Lett"},{"key":"7581_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/ar2784","volume":"11","author":"JH Kappen","year":"2009","unstructured":"Kappen JH, Dik WA, Dingjan GM, van Daele PL, Hooijkaas H, van Hagen PM et al (2009) Cytokines in the colon of a patient with Beh\u00e7et\u2019s disease. Arthritis Res Ther 11:412. https:\/\/doi.org\/10.1186\/ar2784","journal-title":"Arthritis Res Ther"},{"key":"7581_CR8","doi-asserted-by":"publisher","first-page":"109242","DOI":"10.1016\/j.clim.2023.109242","volume":"247","author":"TB van der Houwen","year":"2023","unstructured":"van der Houwen TB, Humer B, Missotten TO, Thiadens A, van Hagen PM, van Laar JAM (2023) Long-term data on efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease. Clin Immunol 247:109242. https:\/\/doi.org\/10.1016\/j.clim.2023.109242","journal-title":"Clin Immunol"},{"key":"7581_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B et al (2015) Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol 13:940-948.e3. https:\/\/doi.org\/10.1016\/j.cgh.2014.08.042","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7581_CR10","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/md.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95:e3863. https:\/\/doi.org\/10.1097\/md.0000000000003863","journal-title":"Medicine (Baltimore)"},{"key":"7581_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/jgh.15754","volume":"37","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liu J, Liu T, Han W, Bai X, Ruan G et al (2022) The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet\u2019s disease, a systematic review and meta-analysis. J Gastroenterol Hepatol 37:608\u2013619. https:\/\/doi.org\/10.1111\/jgh.15754","journal-title":"J Gastroenterol Hepatol"},{"key":"7581_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/jgh.16056","volume":"38","author":"J Park","year":"2023","unstructured":"Park J, Park SJ, Park JJ, Kim TI, Cheon JH (2023) Long-term clinical outcomes of intestinal Beh\u00e7et\u2019s disease: A 30-year cohort study at a tertiary hospital in South Korea. J Gastroenterol Hepatol 38:386\u2013392. https:\/\/doi.org\/10.1111\/jgh.16056","journal-title":"J Gastroenterol Hepatol"},{"key":"7581_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/mr\/roab127","volume":"33","author":"HF Bao","year":"2023","unstructured":"Bao HF, Hou CC, Ye B, Zou J, Luo D, Cai JF et al (2023) Predictors of infliximab refractory intestinal Beh\u00e7et\u2019s syndrome: A retrospective cohort study from the Shanghai Beh\u00e7et\u2019s syndrome database. Mod Rheumatol 33:207\u2013216. https:\/\/doi.org\/10.1093\/mr\/roab127","journal-title":"Mod Rheumatol"},{"key":"7581_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3349\/ymj.2022.0264","volume":"64","author":"SJ Han","year":"2023","unstructured":"Han SJ, Kang EA, Park J, Park SJ, Park JJ, Kim TI et al (2023) Risk factors for surgery in patients with intestinal beh\u00e7et\u2019s disease during anti-tumor necrosis factor-alpha therapy. Yonsei Med J 64:111\u2013116. https:\/\/doi.org\/10.3349\/ymj.2022.0264","journal-title":"Yonsei Med J"},{"key":"7581_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD) (2014) The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347. https:\/\/doi.org\/10.1111\/jdv.12107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"7581_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R et al (2014) The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease: indication of anti-TNF\u03b1 monoclonal antibodies. J Gastroenterol 49:156\u2013162. https:\/\/doi.org\/10.1007\/s00535-013-0872-4","journal-title":"J Gastroenterol"},{"key":"7581_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc 60:505\u2013512. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4","journal-title":"Gastrointest Endosc"},{"key":"7581_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS et al (2011) Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et\u2019s disease. Inflamm Bowel Dis 17:605\u2013613. https:\/\/doi.org\/10.1002\/ibd.21313","journal-title":"Inflamm Bowel Dis"},{"key":"7581_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12876-022-02221-0","volume":"22","author":"H Miyazaki","year":"2022","unstructured":"Miyazaki H, Watanabe D, Okamoto N, Tokunaga E, Ku Y, Takenaka H et al (2022) Efficacy and predictor of anti-TNF\u03b1 agents in patients with intestinal Beh\u00e7et\u2019s disease. BMC Gastroenterol 22:149. https:\/\/doi.org\/10.1186\/s12876-022-02221-0","journal-title":"BMC Gastroenterol"},{"key":"7581_CR20","doi-asserted-by":"publisher","first-page":"175628482311672","DOI":"10.1177\/17562848231167283","volume":"16","author":"K He","year":"2023","unstructured":"He K, Wu D (2023) The treatment principles and targets for intestinal Behcet\u2019s disease. Therap Adv Gastroenterol 16:17562848231167284. https:\/\/doi.org\/10.1177\/17562848231167283","journal-title":"Therap Adv Gastroenterol"},{"key":"7581_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.cgh.2017.02.029","volume":"15","author":"M Lazzerini","year":"2017","unstructured":"Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazz\u00f9 G, Pellegrino S et al (2017) Endoscopic and histologic healing in children with inflammatory bowel diseases treated with thalidomide. Clin Gastroenterol Hepatol 15:1382-1389.e1. https:\/\/doi.org\/10.1016\/j.cgh.2017.02.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7581_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C et al (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65:1211\u20131228. https:\/\/doi.org\/10.1007\/s00228-009-0718-4","journal-title":"Eur J Clin Pharmacol"},{"key":"7581_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10620-012-2351-9","volume":"58","author":"YS Jung","year":"2013","unstructured":"Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH (2013) Clinical course of intestinal Behcet\u2019s disease during the first five years. Dig Dis Sci 58:496\u2013503. https:\/\/doi.org\/10.1007\/s10620-012-2351-9","journal-title":"Dig Dis Sci"},{"key":"7581_CR24","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1038\/s41598-024-55221-3","volume":"14","author":"L Yang","year":"2024","unstructured":"Yang L, Zhang Y, Yao B, Wu Q, Peng L, Yuan L (2024) Timing of first abdominal operation in Crohn\u2019s disease based on a diagnostic model. Sci Rep 14:6099. https:\/\/doi.org\/10.1038\/s41598-024-55221-3","journal-title":"Sci Rep"},{"key":"7581_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K et al (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148:1320\u20139.e3. https:\/\/doi.org\/10.1053\/j.gastro.2015.02.031","journal-title":"Gastroenterology"},{"key":"7581_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","volume":"35","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Wang Y, Oddens BJ, Link R (2012) C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn\u2019s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 35:568\u2013576. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04987.x","journal-title":"Aliment Pharmacol Ther"},{"key":"7581_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13023-021-01772-x","volume":"16","author":"CC Hou","year":"2021","unstructured":"Hou CC, Ye JF, Ma HF, Guan JL (2021) Clinical characteristics and risk factors of intestinal involvement in Beh\u00e7et\u2019s syndrome patients: a cross-sectional study from a single center. Orphanet J Rare Dis 16:132. https:\/\/doi.org\/10.1186\/s13023-021-01772-x","journal-title":"Orphanet J Rare Dis"},{"key":"7581_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","volume":"16","author":"M Fern\u00e1ndez-Ruiz","year":"2018","unstructured":"Fern\u00e1ndez-Ruiz M, Aguado JM (2018) Risk of infection associated with anti-TNF-\u03b1 therapy. Expert Rev Anti Infect Ther 16:939\u2013956. https:\/\/doi.org\/10.1080\/14787210.2018.1544490","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7581_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33:946\u2013964. https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.002","journal-title":"Clin Ther"},{"key":"7581_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","volume":"163","author":"NH Nguyen","year":"2022","unstructured":"Nguyen NH, Solitano V, Vuyyuru SK, MacDonald JK, Syversen SW, J\u00f8rgensen KK et al (2022) Proactive Therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: A systematic review and meta-analysis. Gastroenterology 163:937-949.e932. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.052","journal-title":"Gastroenterology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07581-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:59:41Z","timestamp":1757246381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7581"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07581-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (No. 2023\u20130652).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The institutional review boards of each participating hospital granted a waiver of informed consent, as the study involved de-identified data and was conducted for academic research and model validation purposes only.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}